当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

Abstract：

:The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current study determined whether a BCL2 gene single nucleotide polymorphism (SNP) could affect treatment outcomes in 99 AML patients excluding acute promyelocytic leukemia. Two genotypes were tested, including BCL2 -938 C>A (rs2279115) and +21 A>G (rs1801018). Neither the -938 C>A nor the +21 A>G BLC2 genotype was associated with complete remission (CR) rates following chemotherapy. The -938 A>C BCL2 genotype did not affect leukemia-free survival (LFS), event-free survival (EFS) or overall survival (OS). However, of interest, the BCL2 +21 A>G genotype correlated with LFS, EFS and OS: The group with the +21 AA genotype had a significantly longer median LFS (p<0.001) or EFS (p=0.004), and OS (p=0.04). The multivariate analyses confirmed that this BCL2 gene SNP is an independent prognostic factor for LFS (p=0.05, HR 1.83, 95% C.I. [1.02-3.45]) and EFS (p=0.02, HR 3.13 [1.34-6.43]), but not for OS (p=0.1). This data suggests the involvement of a Bcl-2-mediated mechanism in the development of chemoresistance in AML.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

doi

10.1016/j.leukres.2009.05.009

subject

Has Abstract

pub_date

2010-02-01 00:00:00

pages

166-72

issue

2

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(09)00258-6

journal_volume

34

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.

    abstract：:In this case-control study, interview data on smoking habits were available for 179 de novo cases (116 with cytogenetic data) of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Smoking habits were compared with a pooled set of population controls and hospital controls (diagnosed with malignant melanom...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.10.009

    authors： Björk J,Johansson B,Broberg K,Albin M

    更新日期：2009-06-01 00:00:00

  • Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

    abstract：:In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic int...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2018.09.005

    authors： Leitch HA,Buckstein R,Zhu N,Nevill TJ,Yee KWL,Leber B,Keating MM,St Hilaire E,Kumar R,Delage R,Geddes M,Storring JM,Shamy A,Elemary M,Wells RA

    更新日期：2018-11-01 00:00:00

  • Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.

    abstract：:Osteogenic growth peptide (OGP) increases blood and bone marrow cellularity in mice, and enhances engraftment of bone marrow transplant. Carboxy-terminal pentapeptide (OGP10-14) holds several properties of full-length polypeptide. We evaluated whether synthetic OGP-derived pentapeptide (sOGP10-14) has some activity on...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00091-1

    authors： Fazzi R,Testi R,Trasciatti S,Galimberti S,Rosini S,Piras F,L'Abbate G,Conte A,Petrini M

    更新日期：2002-01-01 00:00:00

  • A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.

    abstract：:Twenty-two patients with myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients receiving supportive care were used as controls. The remission was achieved in 4 patients (18.2%) receiving thalidomide/ATO, and none in the control group (p<0.05). Fifteen of 22 ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.12.023

    authors： Wei W,Zhou F,Zhang Y,Guo L,Shi H,Hou J

    更新日期：2012-06-01 00:00:00

  • The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

    abstract：:AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve patients (six AML; six MDS) were treated with AG-013736 at a dose of 10...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.10.024

    authors： Giles FJ,Bellamy WT,Estrov Z,O'Brien SM,Verstovsek S,Ravandi F,Beran M,Bycott P,Pithavala Y,Steinfeldt H,Reich SD,List AF,Yee KW

    更新日期：2006-07-01 00:00:00

  • In-vitro effects of antineoplastic prostaglandins on human leukemic cell growth and normal myelopoiesis.

    abstract：:The effects of prostaglandin (PG)E1, PGD2 and 9-deoxy-delta 9-PGD2 (PGJ2) on the clonogenic growth of six kinds of human leukemic cell lines (K562, KG1, HL60, U937, THP1 and Molt4) and normal human myeloid progenitor cells (CFU-GM) were studied using semisolid agar cultures. While the degree of suppression of leukemic...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90087-1

    authors： Tsao CJ,Ozawa K,Hosoi T,Urabe A,Takaku F

    更新日期：1986-01-01 00:00:00

  • Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

    abstract：:This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.08.009

    authors： Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

    更新日期：2009-04-01 00:00:00

  • Reversing the multidrug resistance in acute leukemia: until the leukemia initiating cell?

    abstract：:Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38- phenot...

    journal_title：Leukemia research

    pub_type： 评论,社论

    doi：10.1016/j.leukres.2008.09.022

    authors： Costello RT

    更新日期：2009-06-01 00:00:00

  • Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

    abstract：:Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

    journal_title：Leukemia research

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.leukres.2018.07.024

    authors： Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

    更新日期：2018-09-01 00:00:00

  • Dye-mediated photolysis of normal and neoplastic hematopoietic cells.

    abstract：:The purpose of this study was to determine the sensitivity to merocyanine 540 (MC 540)-mediated photolysis of normal human hematopoietic progenitor cells and four leukemia cell lines (Daudi, Raji, K562 and HL-60). Late erythroid progenitors were the most sensitive normal cells. Early erythroid progenitors were of inte...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90104-4

    authors： Sieber F,Stuart RK,Rowley SD,Sharkis SJ,Sensenbrenner LL

    更新日期：1987-01-01 00:00:00

  • Detoxification and DNA repair genes polymorphisms and susceptibility of primary myelodysplastic syndromes in Chinese population.

    abstract：:Molecular epidemiological studies have found new insights into the etiology of myelodysplastic syndromes (MDS). We analyzed the polymorphisms of 5 genes in 275 patients with primary MDS and 354 healthy controls in an attempt to identify candidate genetic risk factors for primary MDS in Chinese Han population. There wa...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.12.001

    authors： Li L,Yang L,Zhang Y,Xu Z,Qin T,Hao Y,Xiao Z

    更新日期：2011-06-01 00:00:00

  • Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.

    abstract：:Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2014.02.008

    authors： Mark TM,Coleman M,Niesvizky R

    更新日期：2014-05-01 00:00:00

  • Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

    abstract：:Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90251-1

    authors： Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

    更新日期：1986-01-01 00:00:00

  • Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: specific delta rearrangement pattern does not involve J delta gene locus.

    abstract：:We have analysed the configuration of immunoassociated genes and the karyotypes of 30 patients with acute myelocytic leukemia (AML) and 10 with chronic myelocytic leukemia in blast crisis (CML-BC). In AML, the frequencies of T-cell receptor (TcR) beta, gamma, and delta chain and immunoglobulin heavy and light chain ge...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90070-a

    authors： Akiyoshi TT,Kimura N,Uike N,Kozuru M,Tamura K,Takihara Y,Hisano S,Nishimura J,Kikuchi M

    更新日期：1991-01-01 00:00:00

  • Acute leukemia, a rare but fatal complication after liver transplantation.

    abstract：:Little information is available about the risk factors and means to improve the survival rate of acute leukemia in a rare but often fatal complication after liver transplantation (LT). We report the development of AML-M2 in one of the 764 patients who underwent liver transplantation at our center, and review the liter...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.035

    authors： Jiang N,Li H,Wang GS,Zhang J,Zhang JF,Yi SH,Yang Y,Cai CJ,Lu MQ,Chen GH

    更新日期：2009-10-01 00:00:00

  • Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).

    abstract：:The resistance to all trans retinoic acid (ATRA) differentiating treatment is a consequence, in most of the cases, of either increased catabolism or down regulation of ATRA uptake. Recently, we have shown that ATRA efficiency to differentiate HL-60 cells was enhanced about 30 times after its incorporation into Low Den...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(00)00019-9

    authors： Gueddari N,Madoulet C,Lefebvre P,Berthou L,Chomienne C,Jardillier JC

    更新日期：2000-06-01 00:00:00

  • KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.

    abstract：:Gain-of-function mutations in the proto-oncogene c-kit that induce constitutive kinase activity of its product, KIT protein, are characteristic of human mast cell disease and are believed to play a central role in mast cell leukemia oncogenesis, proliferation and survival. Nuclear overexpression of the Wnt effector be...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.08.023

    authors： Kajiguchi T,Lee S,Lee MJ,Trepel JB,Neckers L

    更新日期：2008-05-01 00:00:00

  • Mutation screening for JAK2V617F: when to order the test and how to interpret the results.

    abstract：:With the application of adequately sensitive tests, it is now becoming evident that more than 90% of patients with conventionally-defined polycythemia vera (PV) carry the somatic JAK2V617F mutation in their granulocytes. However, the specific mutation is also found in other classic and atypical myeloproliferative diso...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.01.004

    authors： Tefferi A,Pardanani A

    更新日期：2006-06-01 00:00:00

  • Relationship between cyclin D1 and p21(Waf1/Cip1) during differentiation of human myeloid leukemia cell lines.

    abstract：:Expression of cell cycle-regulating genes was studied in human myeloid leukemia cell lines ML-1, ML-2 and ML-3 during induction of differentiation in vitro. Myelomonocytic differentiation was induced by phorbol ester (12-o-Tetradecanoyl-phorbol-13-acetate, TPA), tumor necrosis factor alpha (TNFalpha) or interferon gam...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(03)00103-6

    authors： Ullmannová V,Stöckbauer P,Hradcová M,Soucek J,Haskovec C

    更新日期：2003-12-01 00:00:00

  • Benzyl isothiocyanate inhibits murine WEHI-3 leukemia cells in vitro and promotes phagocytosis in BALB/c mice in vivo.

    abstract：:Many evidences have shown that dietary intake of cruciferous vegetables could protect against the risk of various types of malignancies. Benzyl isothiocyanate (BITC), one of the compounds from cruciferous vegetables, had shown induced cell cycle arrest and apoptosis in cancer cells. However, there is no available info...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.01.030

    authors： Tsou MF,Peng CT,Shih MC,Yang JS,Lu CC,Chiang JH,Wu CL,Lin JP,Lo C,Fan MJ,Chung JG

    更新日期：2009-11-01 00:00:00

  • High Th1/Th2 ratio in patients with multiple myeloma.

    abstract：:To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.06.003

    authors： Ogawara H,Handa H,Yamazaki T,Toda T,Yoshida K,Nishimoto N,Al-ma'Quol WH,Kaneko Y,Matsushima T,Tsukamoto N,Nojima Y,Matsumoto M,Sawamura M,Murakami H

    更新日期：2005-02-01 00:00:00

  • Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

    abstract：:We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL). Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy mode...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00175-8

    authors： Sotomayor EM,Piantadosi S,Miller CB,Karp JE,Jones RJ,Rowley SD,Kaufmann SH,Braine H,Burke PJ,Gore SD

    更新日期：2002-05-01 00:00:00

  • Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha.

    abstract：:Pro-apoptotic signalling upon toll-like receptor (TLR) stimulation in myeloid cells is normally antagonized by the simultaneous activation of anti-apoptotic pathways. We have previously reported that IFN-alpha can sensitize human monocytes to apoptosis induction by lipopolysaccharide (LPS). Based on these results we i...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.05.001

    authors： Lehner M,Bailo M,Stachel D,Roesler W,Parolini O,Holter W

    更新日期：2007-12-01 00:00:00

  • Dietary bioflavonoids induce apoptosis in human leukemia cells.

    abstract：:Dietary bioflavonoids are secondary metabolites of plants that are known to have a variety of bio-effects, including anti-cancer activity. In this study, we examined the effects of flavonoids on the growth of human leukemia cells and found that certain flavonoids induce apoptosis in a variety of human leukemia cells. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.11.015

    authors： Matsui J,Kiyokawa N,Takenouchi H,Taguchi T,Suzuki K,Shiozawa Y,Saito M,Tang WR,Katagiri YU,Okita H,Fujimoto J

    更新日期：2005-05-01 00:00:00

  • The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

    abstract：PURPOSE:To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia. PATIENTS AND METHODS:We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolle...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2019.01.007

    authors： Medeiros BC,Othus M,Tallman MS,Sun Z,Fernandez HF,Rowe JM,Lazarus HM,Appelbaum FR,Luger SM,Litzow MR,Erba HP

    更新日期：2019-03-01 00:00:00

  • Hemopoietic features of splenectomized mice bearing IL-3 producing T cell leukemia.

    abstract：:Hemopoietic responses were studied in splenectomized mice after transplantation of the hemopoietic colony stimulating activity producing leukemia, L8313. In non-splenectomized mice, the number of peripheral leukocytes was elevated to 4 x 10(5)/mm3 after transplantation. In contrast, it was below 1.7 x 10(4)/mm3 in spl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90159-8

    authors： Sawada H,Sugimoto K,Aramaki K,Mori KJ

    更新日期：1989-01-01 00:00:00

  • Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma.

    abstract：:The present study explored the effects of Forkhead box Q1 (FOXQ1) on cell proliferation, cell cycle and apoptosis via the Sonic hedgehog (Shh) pathway in Natural killer/T-cell lymphoma (NKTCL). Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to detect FOXQ1 expression in 117 NKTCL patients and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.11.001

    authors： Liu P,Chen L

    更新日期：2018-01-01 00:00:00

  • Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study.

    abstract：:Imatinib mesylate (IM) is the treatment of choice in patients with newly diagnosed chronic myeloid leukemia (CML), irrespectively of their age. Nevertheless, information regarding tolerability and responses in advanced-age patients, a subgroup in which co-morbidities and other factors may influence outcome, is scarce,...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.leukres.2011.01.017

    authors： Sánchez-Guijo FM,Durán S,Galende J,Boqué C,Nieto JB,Balanzat J,Gracia A,García I,Avellaneda-Molina C,Moreno MV,Luño-Fernandez E,Hermosilla M,Sanchez-Varela JM,Dios A,López-Garrido P,Giraldo P,Bargay J,Domingo JM,Soler

    更新日期：2011-09-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract：:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.015

    authors： Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期：2015-07-01 00:00:00

  • Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts.

    abstract：:The K562 leukemia cell line has been extensively used in studies of erythroid differentiation but it has been less well appreciated that treatment of K562 cells with the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) leads to loss of their erythroid properties and to acquisition of several megakaryoblastoi...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(90)90002-q

    authors： Alitalo R

    更新日期：1990-01-01 00:00:00